



QML
List of Accredited Methods (Flexible Scope Category II)

QML
402-2e

Page: 1 of 12

Version: 00
Valid from:
17.03.2021

Status: 17-Mar-2021

Precision for Medicine GmbH

FLEXIBLE SCOPE OF ACCREDITATION CATEGORY II
(DIN EN/ISO 17025:2018)

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_1e_Rev07, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu FoxP3 (Tregs)/ quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_1e_Rev07, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CD3+ Cells / quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche

Replaces Version No.: / from: /	Generated by: J. Bartsch Generated on: 15.03.2021	Checked by: J. Held Checked on: 17.03.2021	Approved by: S. Olek Valid from: 17.03.2021
Signatures:			

Status: 17-Mar-2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CCR6+ Cells / quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_2_Rev05, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_1e_Rev07, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03, QMA 510-4e_Rev00	hu GNLY+ Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu NK Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche

Status: 17-Mar-2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_1e_Rev07, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu B Cells / quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_1e_Rev07, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu neutrophile Granulocytes/ quantitative RT-PCR	Human Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu naive CD8-T+ Cells/ quantitative RT-PCR	Human Suspension Cells	Light Cyclor 480 Roche

Status: 17-Mar-2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_7e_Rev00, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev01 Rev02, QMA 510-3e_Rev03, QMA 510-4e_Rev00	hu Th17 Cells / quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_1e_Rev07, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CD4 Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_1e_Rev07, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CD8 Cells / quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche

Status: 17-Mar-2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu TFH Cells/ quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu Monocytes / quantitative RT-PCR	Human Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu Eosinophils /quantitative RT-PCR	Human Suspension Cells	Light Cyclor 480 Roche

Status: 17-Mar-2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu Basophils /quantitative RT-PCR	Human Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu monocytic MDSC Cells /quantitative RT-PCR	Human Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu PD1 + Cells /quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche

Status: 17-Mar-2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu non-classical Monocytes /quantitative RT-PCR	Human Suspension Cells	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu pDC+ Cells/quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CXCR3+ Cells/quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyler 480 Roche

Status: 17-Mar-2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu LAG3+ Cells/quantitative RT-PCR	Human Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu memory B Cells/quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu S1PR1+ Cells/quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche

Status: 17-Mar-2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8eAnnex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CCR7+ Cells/quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8eAnnex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu ITGA4+ Cells/quantitative RT-PCR	Human Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8eAnnex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu PTGFRB+ Cells/quantitative RT-PCR	Human Suspension Cells	Light Cyclor 480 Roche

Status: 17-Mar-2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu CRTH2+ Cells/quantitative RT-PCR	Human Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu S1PR5+ Cells/quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8e Annex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu GATA3+ Cells / quantitative RT-PCR	Human Tissue and Suspension Cells	Light Cyclor 480 Roche

Status: 17-Mar-2021

Method/ Version	Analyte/ Test technology	Test material (matrix)	Test equipment
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8eAnnex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu COL1A1/quantitative RT-PCR	Human Suspension Cells	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8eAnnex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu memCD4/quantitative RT-PCR	Human Suspension Cells	Light Cyler 480 Roche
QMA 509-4_Rev00, QMA 509-5_Rev00, QMA 504-1_1e_Rev07, QMA 504-1_4e_Rev05, QMA 504-1_7e_Rev03, QMA 504-1_8_Rev02, QMA 504-2_20e_Rev03, QMA 504-2_23e_Rev02, QMA 504-2_8eAnnex1_Rev01, QMA 504-2_13e_Rev04, QMA 504-5e_Rev06, QMA 506-1e_Rev03, QMA 508-1e_Rev03, QMA 508-2e_Rev10, QMA 509-2e_Rev02, QMA 509-3e_Rev02, QMA 510-1e_Rev07, QMA 510-2e_Rev02, QMA 510-3e_Rev03; QMA 510-4e_Rev00	hu naive B Cells/ quantitative RT-PCR	Human Suspension Cells	Light Cyler 480 Roche

Status: 17-Mar-2021

Abbreviations used:

DIN	Deutsches Institut für Normung e.V.
EN	European Standard
FFPE	Formalin-fixed, Paraffin-embedded
hu	human
ISO	International Organization for Standardization
RT-PCR	Real-Time Polymerase Chain Reaction
IEC	International Electrotechnical Commission